This Medudy course is a video tutorial for physicians on the topic of “Approval of a denosumab biosimilar.”
Dr. Peer Aries, Head of the Immunology Department in Hamburg, and Prof. Dr. Axel Merseburger, Director of the Department of Urology at the University Medical Center Schleswig-Holstein, present practical insights in this video regarding the approval and use of a biosimilar successor to denosumab. Denosumab is an established biologic used in the treatment of osteoporosis, which is also employed in the treatment of cancer-related bone diseases. Therefore, Dr. Aries and Dr. Merseburger will first discuss the approval of the biosimilar for osteoporosis and, in the second part, the extension of the approval by extrapolation for oncological indications.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was made possible with the generous support of Sandoz Hexal.
At the end of this training you will know:
- the mechanism of action of denosumab
- the results of the ROSALIA study
- the approved indications for the denosumab biosimilar
- the clinical relevance of the approval for real-world care
